Objective: Bladder cancers are classified into two groups as urothelial and non-urothelial cancer (NUBC). In this study, we investigated the clinicopathological features and treatment responses in patients with NUBC who were diagnosed and treated in our center.

Methods: The patients who were diagnosed and treated in our hospital between 2006 and 2017 were included in the study retrospectively. Patients with urothelial or mixed bladder cancers were excluded from the study.

Results: A total of 16 patients with NUBC were included in the study. Six patients had squamous cell carcinoma, six patients had small cell carcinoma and four patients had adenocarcinoma. Thirteen patients (81%) were male and three were female. Although there was no statistically significant difference between the groups in terms of localization of metastases (p=0.663), the most common site of metastasis was pelvic structures in squamous cell carcinoma group and multiple distant organ metastasis were observed in small cell carcinoma group. The median survival in squamous cell carcinoma, adenocarcinoma, and small cell carcinoma was 11±5.3, 12±10, and 2±1.8 months, respectively (logrank p=0.329).

Conclusion: There are no large prospective randomized clinical studies to guide treatment in NUBC. In the light of these results, we recommend that these patients should participate in prospective clinical studies.